EC Conditionally Approves Cell Therapeutics’ Pixantrone for Non-Hodgkin Lymphoma

Firm will immediately make drug available, initially on a named-patient basis.

Funds Won for Oral T-Cell Cancer Vaccine Platform

Swiss-German cancer vaccines firm Vaximm said its German subsidiary received a grant through BioRN to support expansion of its oral T-cell vaccine technology platform.

F-star, Merck Agree Up to €1B Deal to Develop Five Bispecific...

Deal includes F-star's bispecific antibody targeting LAG-3 and PD-L1; Merck will pay €115 upfront plus R&D funding and milestones, and has option to acquire exclusive development and commercialization rights to the antibodies after F-star delivers predefined data packages

Breast Cancer Trial: First-Line Chemo-Immuno Combo Improves Outcomes

A large Phase III trial, the Impassion130 trial, has produced results supporting the use of chemotherapy plus immunotherapy as first-line treatment in certain patients...

New GPCR Receptor Fingerprints Could Boost Drug Development Efforts

Researchers create GPCR fingerprints that may prove useful in a wide range of therapeutic applications

Epigenetic Reprogramming May Boost Immunotherapy

Altering DNA methylation may reverse T-cell exhaustion, improve checkpoint blockade

Mithra’s E4 Estrogen Wins EU Orphan Drug Designation for Treating HIE...

Belgian women’s health specialist Mithra received orphan drug designation (ODD) from the European Medicines Agency (EMA) for its estrogen candidate, estetrol (E4) as a treatment for neonatal encephalopathy (NE). The firm intends to develop the drug for treating hypoxic ischemic encephalopathy (HIE), and will look for a partner for clinical development.

Taking Aim at Peripheral Neuropathy and Neurodegeneration Targets

Expanding on research from the Neurodegeneration Consortium and other entities, Magnolia Neurosciences hopes to develop drugs for peripheral neuropathy and “chemobrain.”

CRISPR Human Knockout Screens Identify New Target for ALS

U.S. researchers have used CRISPR/Cas9 screens to identify genes that may protect against or promote the toxicity of protein aggregates in amyotrophic lateral sclerosis (ALS).

Sanofi, Evotec Launch New “BRIDGE” Partnership to Accelerate Drug Discovery

Evotec said today it will join Sanofi in partnering with academic institutions to translate their research into new small-molecule drugs across multiple unspecified therapeutic...

Recently Featured

Scroll Up